Animal models of tardive dyskinesia - A review

Indian Journal of Physiology and Pharmacology

Volumn 45, Issue 2, 2001, Pages 148-160

  Kulkarni, S K ^a   Naidu, P S ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Animal models; Isoniazid; Neuroleptics; Pathophysiology; Reserpine; Tardive dyskinesia; Vacuous chewing movements

Indexed keywords

AMPHETAMINE; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; CAFFEINE; CHLORPROMAZINE; DOPAMINE RECEPTOR; ESTROGEN; ISONIAZID; LEVODOPA; METOCLOPRAMIDE; NARCOTIC AGENT; NEUROLEPTIC AGENT; PHENYTOIN; RESERPINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANIMAL MODEL; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG TARGETING; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; GABAERGIC SYSTEM; MASTICATION; METHODOLOGY; NEUROCHEMISTRY; NONHUMAN; OROFACIAL DYSKINESIA; PATHOPHYSIOLOGY; PHENOMENOLOGY; REVIEW; RODENT; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TOXICITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; FREE RADICALS; GAMMA-AMINOBUTYRIC ACID; HUMANS; ISONIAZID; RECEPTORS, DOPAMINE; RESERPINE;

EID: 0034987979     PISSN: 00195499     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Tardive dyskinesia: Pathophysiology
2. Tardive dystonia: Prevalence, risk factors and comparison with tardive dyskinesia in a population of two hundred acute psychiatric in patients
3. Tardive syndromes and other drug-induced movement disorders
4. Tardive dyskinesia: Epidemiological and clinical presentation
5. Ein eigentumliches syndrom in oralen bereich bei megaphen applikation
6. Neurological symptoms in pharmacotherapy in psychosis
7. Spontaneous involuntary disorders of movement
8. Abnormal involuntary movements and psychosis in the preneuroleptic era and in unmedicated patients: Implications for the concept of tardive dyskinesia
9. Dyskinesias associated with tricyclic antidepressants
10. Tardive dyskinesia in the course of antidepressant therapy: A prevalence study and review of literature
11. Oral-buccal dyskinesia symptoms associated with low-dose benzodiazepine treatment
12. Anticonvulsant-induced dyskinesias: A comparison with dyskinesias induced by neuroleptics
13. Neuroleptic-induced dyskinesia in children
14. Implications of amphetamine-induced stereotyped as a model for tardive dyskinesia
15. Extrapyramidal reactions with metoclopramide
16. 1 antihistaminic medications
17. Orofacial dyskinesia associated with prolonged use of antihistaminic decongestants
18. Tardive dyskinesia: Prevalence and risk factors, 1959-1979
19. Tardive dyskinesia
20. Gender differences in tardive dyskinesia: A critical review if the literature
21. Theoretical implications of the use of L-dopa parkinsonism
22. Spontaneous orofacial movements induced in rodents very long-term neuroleptic drug administration: Phenomenology, Pathophysiology and putative relationship to tardive dyskinesia
23. Neurobiological substrates of tardive dyskinesia: The GABA hypothesis
24. 2 receptors
25. Treatment of tardive dyskinesia
26. Tardive dyskinesia: Pathophysiology and animal models
27. Abnormal involuntary movements in schizophrenia: Are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors?
28. Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug (flupenithixol) in rats
29. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis
30. Brain γ-aminobutyric acid abnormality in tardive dyskinesia
31. Duplication of biochemical changes of Huntigton's chorea by intrastriatal injections of glutamic and kinic acids
32. Excitotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia
33. Depolarization inactivation of dopamine neurons: Terminal release characteristics
34. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations
35. Chronic haloperidol potentiate stimulated glutamate release in caudate putamen, but not prefrontal cortex
36. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia
37. An animal model for coexisting tardive dyskinesia and tardive parkinsonism: A glutamate hypothesis for tardive dyskinesia
38. Neurotoxicity associated with neuroleptic induced oral dyskinesias in rats implications for tardive dyskinesia?
39. Free radicals and tardive dyskinesia
40. Free radial mechanism in schizophrenia and tardive dyskinesia
41. Oxidative stress glutamate and neurodegenerative disorders
42. Striatal dopamine metabolism increases during long-term haloperidol administration in rats but shows tolerance in response to acute challenge with raclopride
43. Tardive dyskinesia: Possible involvement of free radical and treatment with vitamin E
44. Oxygen radicals diminish dopamine transporter function in rat striatum
45. Oxidative stress-resistant cells are protected against haloperidol toxicity
46. Induction of reactive oxygen species in neurons by haloperidol
47. Induction of NF-kappaB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: Suppression of NF-kappaB and neuroprotection by antioxidants
48. Response of striatonigral substance P systems to a dopamine receptor agonist and antagonist
49. Substance P content of substantia nigra after chronic treatment with anti-schizophrenic drugs
50. Intranigral infusions of enkephalins elicits dyskinetic biting in rats
51. 2 receptor antagonists
52. Effects of neurotensin in a rodent model of tardive dyskinesia
53. 1 receptors
54. Animal models in psychiatric research
55. A scaling approach to find order parameters quantifying the effects of dopaminergic agents on unconditioned motor activity in rats
56. Animal models of acute drug-induced akathisia - A review
57. Tardive dyskinesia: Animal models
58. Haloperidol-induced tardive dyskinesia in monkeys
59. The effect of chronic neuroleptic administration on cerebral dopamine receptor function
60. Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration
61. Neuroleptic-induced vacuouis chewing movements as an animal model of tardive dyskinesia: A study in three rat strains
62. Chronic olanzepine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol
63. An experimental model of tardive dyskinesia
64. Cerebral dopamine function in rats following with drawl from one year of continuous neuroleptic administration
65. Oral dyskinesia in rats following brain lesions and neuroleptic drug administration
66. Oral dyskinesia in brain damaged rats withdrawn from a neuroleptic: Implications for models of tardive dyskinesia
67. Pharmacological characterization of spontaneous or drug-associated purposeless chewing movements in rats
68. Dose-dependent increase in rat spontaneous chewing rates during long-term administration of haloperidol but not clozapine
69. Neuroleptic-induced oral dyskinesias: Effects of progabide and lack of correlation with regional changes in glutamic acid decarboxylase and choline acetyl transferase activities
70. 2 agonist LY171555 on oral movements in rats
71. Behavioral consequences of long-term treatment with neuroleptic drugs
72. Reduction of nigral glutamic acid decarboxylase in rats with neuroleptic-induced oral dyskinesia
73. Study on the suitability of a rat model for tardive dyskinesia and the preventive effects of various drugs
74. Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats
75. Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy
76. Behavioral and neurochemical effects of chronic administration of reserpine and SKF38393 in rats
77. Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment
78. Acute reserpine administration elicits long-term spontaneous oral dyskinesia
79. Dose dependent differences in the development of reserpine-induced oral dyskinesia in rats: Support for a model of tardive dyskinesia
80. GABAergic denervation of rat substantia nigra: Functional and pharmacological properties
81. Oral movements induced by interference with nigral GABA neurotransmission: Relationship to tardive dyskinesia
82. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis
83. Expression of glutamic acid decarboxylase mRNA in striatum and pallidum in an animal model of tardive dyskinesia